- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07262619
EIK1005-002: Kliininen tutkimustutkimus, jossa arvioidaan EIK1005:ää, Werner-helicasa-estäjää, monoterapiana ja yhdistelmänä pembrolitsumabin kanssa potilailla, joilla on kehittyneitä kiinteitä kasvaimia, mukaan lukien mikrosatelliittinstabiiliuden korkeat (MSI-H) kasvaimet
Monikeskuksinen, moniosainen, vaiheen 1/2 tutkimus EIK1005:sta yksilöllisenä hoitona ja yhdistettynä pembrolizumabiin edenneiden kiinteiden kasvainten potilailla, mukaan lukien tarkistuspisteen estäjälle kokemattomilla potilailla, joilla on mikrosatelliittivakavuus korkea (MSI-H) tai virhekorjauksen puutos (dMMR) kasvaimet
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
This Phase 1/2 study (EIK1005-002) will investigate the safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of EIK1005 as a monotherapy and in combination with pembrolizumab in participants with advanced solid tumors, including participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors.
The study will be conducted in 2 parts: Part 1 and Part 2, with Part 1 being further divided into Part 1A and Part 1B as described below:
- Part 1A (monotherapy dose escalation): participants will receive EIK1005 only.
- Part 1B (combination dose escalation): participants will receive EIK1005 in combination with pembrolizumab.
- Part 2 (dose optimization): participants will be randomized 1:1 to monotherapy with EIK1005 at one of the two selected doses from Part 1A to identify the dose of EIK1005 in monotherapy for subsequent studies.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 2
- Vaihe 1
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Ana C Mamede, PharmD
- Puhelinnumero: 347-806-4584
- Sähköposti: mamedea@eikontx.com
Tutki yhteystietojen varmuuskopiointi
- Nimi: Krishna Kaza
- Sähköposti: kazak@eikontx.com
Opiskelupaikat
-
-
New South Wales
-
Saint Leonards, New South Wales, Australia
- Ei vielä rekrytointia
- GenesisCare North Shore (Oncology)
-
Waratah, New South Wales, Australia
- Rekrytointi
- Calvary Mater Newcastle Hospital
-
-
Victoria
-
Ballarat, Victoria, Australia
- Rekrytointi
- Grampians Health
-
Camperdown, Victoria, Australia
- Rekrytointi
- Chris O'Brien Lifehouse (Sydney Cancer Centre)
-
Frankston, Victoria, Australia
- Rekrytointi
- Peninsula and Southeast Oncology (PASO) Medical
-
Frankston, Victoria, Australia, 3199
- Rekrytointi
- Oncology Clinics Victoria (OCV) - Cabrini Brighton Hospital
-
-
-
-
-
Brussels, Belgia, 1020
- Rekrytointi
- Centre Hospitalier Universitaire Brugmann - Victor Horta
-
-
-
-
-
Barcelona, Espanja, 08023
- Rekrytointi
- START - Barcelona
-
Logroño, Espanja, 26006
- Rekrytointi
- START Rioja - Hospital de San Pedro
-
Madrid, Espanja, 28233
- Rekrytointi
- NEXT Madrid HUQSM
-
Zaragoza, Espanja, 50009
- Rekrytointi
- Hospital Universitario Miguel Servet
-
-
Balearic Islands
-
Palma, Balearic Islands, Espanja, 07120
- Rekrytointi
- Hospital Universitari Son Espases
-
-
Barcelona
-
Barcelona, Barcelona, Espanja, 8036
- Rekrytointi
- Hospital Clinic Barcelona
-
-
-
-
-
Seoul, Etelä -Korea, 02841
- Rekrytointi
- Korea University Anam Hospital
-
Suwon, Etelä -Korea, 16499
- Rekrytointi
- Ajou University School of Medicine & Graduate School of Medicine
-
-
Busan
-
Busan, Busan, Etelä -Korea, 48108
- Rekrytointi
- Inje University-Haeundae Paik Hospital
-
-
-
-
-
Rome, Italia, 00128
- Rekrytointi
- Campus Bio-Medico di Rome University
-
-
-
-
-
Linz, Itävalta, 4020
- Rekrytointi
- Ordensklinikum Linz Elisabethinen
-
-
-
-
-
Oslo, Norja, 0379
- Rekrytointi
- Oslo University
-
-
-
-
-
Lisbon, Portugali, 1649-028
- Rekrytointi
- Hospital de Santa Maria
-
Loures, Portugali, 2674-514
- Rekrytointi
- Unidade Local de Saúde (ULS) Loures Odivelas
-
Porto, Portugali, 4200
- Rekrytointi
- Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO Porto)
-
-
Lisbon District
-
Lisbon, Lisbon District, Portugali, 1500-650
- Rekrytointi
- Hospital da Luz Lisboa
-
-
-
-
-
Krakow, Puola, 31-864
- Rekrytointi
- GCPMED Sp. z o.o., Centrum Medyczne iMed24
-
Lodz, Puola, 90-338
- Rekrytointi
- Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna
-
-
West Pomeranian Voivodeship
-
Szczecin, West Pomeranian Voivodeship, Puola, 70-419
- Rekrytointi
- One Day Med
-
-
-
-
Rhone
-
Pierre-Bénite, Rhone, Ranska, 69310
- Rekrytointi
- Hospices Civils De Lyon (hcl) -Centre Hospitalier Lyon-Sud
-
-
-
-
-
Berlin, Saksa, 13125
- Rekrytointi
- Helios Klinikum Berlin-Buch
-
Hamburg, Saksa, 22297
- Rekrytointi
- Norddeutsches Studienzentrum fur Innovative Onkologie (NIO) Hamatologisch Onkologische Praxis Eppendorf (HOPE)
-
-
Bavaria
-
Deggendorf, Bavaria, Saksa, 94469
- Rekrytointi
- DONAUISAR Klinikum
-
-
-
-
-
Singapore, Singapore, 119074
- Rekrytointi
- National University Hospital (NUH)
-
-
Central Region
-
Singapore, Central Region, Singapore, 168583
- Rekrytointi
- National Cancer Centre Singapore (NCCS)
-
-
-
-
-
Kuopio, Suomi, 70210
- Rekrytointi
- Kuopio University Hospital
-
-
-
-
-
Wellington, Uusi Seelanti
- Rekrytointi
- Health New Zealand
-
-
Manawatu
-
Roslyn, Manawatu, Uusi Seelanti, 4414
- Rekrytointi
- Palmerstone North Hospital
-
-
-
-
California
-
Los Angeles, California, Yhdysvallat, 90027
- Rekrytointi
- California Research Institute (CRI)
-
-
Florida
-
Doral, Florida, Yhdysvallat, 33172
- Rekrytointi
- Omnicure Clinical Research
-
Hialeah, Florida, Yhdysvallat, 33013
- Rekrytointi
- Bioresearch Partner
-
Plantation, Florida, Yhdysvallat, 33322
- Rekrytointi
- Florida Clinical Trials Group
-
Tamarac, Florida, Yhdysvallat, 33321
- Rekrytointi
- Florida Clinical Trials Group - Tamarac
-
-
New Jersey
-
Morristown, New Jersey, Yhdysvallat, 07960
- Rekrytointi
- Morristown Medical Center
-
-
New York
-
Lake Success, New York, Yhdysvallat, 11042
- Rekrytointi
- START New York-Long Island
-
New York, New York, Yhdysvallat, 10022
- Rekrytointi
- Memorial Sloan Kettering Cancer Center (MSKCC)
-
-
Texas
-
Fort Worth, Texas, Yhdysvallat, 76104
- Rekrytointi
- START Dallas Fort Worth
-
Houston, Texas, Yhdysvallat, 77030
- Rekrytointi
- University of Texas MD Anderson Cancer Center
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Key Inclusion Criteria:
- is ≥ 18 years of age at the time of signing the informed consent.
- has a life expectancy of at least 3 months.
- has histologically or cytologically documented advanced (unresectable and/or metastatic) solid tumor. Part 1A: recommend that participants have archival tissue not more than 3 years old. Part 1B and Part 2: participant has locally confirmed Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) tumor. Participant must have archival tumor tissue (not more than 3 years old) for retrospective confirmation of MSI-H or dMMR tumor by a central laboratory.
- In Part 1A, has received and then progressed after or is intolerant to at least 1 standard treatment regimen in the advanced setting. The participant does not have alternative therapeutic options per PI's medical judgement. Preference should be given to: (1) participants with MSI-H or dMMR cancers that have progressed after checkpoint inhibitor (CPI) therapy and (2) participants with microsatellite stable cells (MSS) cancers that have progressed following at least one regimen of platinum, alkylating or topoisomerase containing chemotherapy.
- has measurable disease at baseline according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the PI.
- has an Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.
- has an adequate organ and marrow function.
Key Exclusion Criteria:
- has not recovered (i.e., to Grade ≤ 1 or to baseline) from prior anti-cancer therapy-induced adverse events (AEs).
- has received prior treatment with Werner (WRN) inhibitor.
- has a history of relevant drug hypersensitivity, ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients, history of serious allergic reactions leading to hospitalization, or any other allergic reaction in general.
- In Parts 1B and Part 2 Rescue: diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.
- has known additional malignancy that is progressing or has required active treatment within the past 3 years.
- has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study treatment.
- has mean resting QTcF > 470 ms (men and women) obtained from triplicate electrocardiograms (ECGs).
- has active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Participants may enroll with the following conditions: Type 1 diabetes, hypothyroidism requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia not requiring systemic treatment).
- has history of (non-infectious) pneumonitis/pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease.
- has active tuberculosis.
- has any active infections requiring systemic therapy.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Part 1A (Dose escalation, Monotherapy)
EIK1005 will be given as monotherapy in participants without alternative treatment options. |
EIK1005 is a selective inhibitor of the Werner helicase. |
|
Kokeellinen: Part 1B (Dose escalation, Combination with pembrolizumab)
EIK1005 will be given in combination with pembrolizumab to participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) solid tumors. |
EIK1005 is a selective inhibitor of the Werner helicase. Pembrolizumab is a PD-1 inhibitor. |
|
Kokeellinen: Part 2 (Dose optimization, Monotherapy)
Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) advanced solid tumors will be randomized to receive EIK1005 monotherapy at one of the two identified doses selected from Part 1A. |
EIK1005 is a selective inhibitor of the Werner helicase. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Dose-Limiting Toxicity (DLT) - Part 1
Aikaikkuna: 21 Days
|
A DLT is a protocol-defined adverse event occurring during the DLT observation period. |
21 Days
|
|
Adverse Events (AEs) - Part 1 and Part 2
Aikaikkuna: From the time of first dose of study medication through 30 days following cessation of study treatment.
|
Number of participants reporting adverse events or serious adverse events. |
From the time of first dose of study medication through 30 days following cessation of study treatment.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Objective Response (OR) - Part 1 and Part 2
Aikaikkuna: Through study completion, an average of 2 years.
|
OR defined as participants who have a complete response [CR] or partial response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Duration of Response (DOR) - Part 1 and Part 2
Aikaikkuna: Through study completion, an average of 2 years.
|
DOR (defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, in participants demonstrating CR or PR) by RECIST 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Disease Control (DC) - Part 1 and Part 2
Aikaikkuna: Through study completion, an average of 2 years.
|
DC defined as participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD) by RECIST 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Progression-free survival (PFS) - Part 2
Aikaikkuna: Through study completion, an average of 2 years.
|
PFS defined as the time from randomization to the first documented disease progression by RECIST 1.1 as assessed by the Investigator or death due to any cause, whichever occurs first. |
Through study completion, an average of 2 years.
|
|
Pharmacokinetic (PK) parameters of EIK1005 - AUC0-24 (Part 1 and Part 2)
Aikaikkuna: Up to 1 year
|
AUC0-24 (Area Under the plasma Concentration versus time curve from 0 to 24 hours): Measures total drug exposure over the first 24 hours after dosing of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - AUCtau,ss (Part 1 and Part 2)
Aikaikkuna: Up to 1 year
|
AUCtau,ss [Area Under the plasma Concentration versus time curve over one dosing interval (tau) at steady state]: Reflects average drug exposure during each dosing interval once the steady state has been reached for EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - Cmax (Part 1 and Part 2)
Aikaikkuna: Up to 1 year
|
Cmax (Maximum Plasma Concentration) after dose administration of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - tmax (Part 1 and Part 2)
Aikaikkuna: Up to 1 year
|
tmax (the time required for the plasma concentration of the drug to reach maximum concentration after dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - t½ (Half-life) (Part 1 and Part 2)
Aikaikkuna: Up to 1 year
|
Half-life (the time required for the plasma concentration of the drug to decrease by 50% after the dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Tutkijat
- Opintojohtaja: Nilou Mobashery, MD, Eikon Therapeutics, Inc.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Urogenitaaliset sairaudet
- Sukuelinten sairaudet
- Patologiset prosessit
- Urogenitaaliset kasvaimet
- Neoplasmat sivustoittain
- Neoplasmat
- Naisten virtsa- ja sukupuolielinten sairaudet
- Naisten virtsa- ja sukupuolielinten sairaudet ja raskauden komplikaatiot
- Kohdun sairaudet
- Sukuelinten sairaudet, naiset
- Neoplastiset prosessit
- Sukuelinten kasvaimet, naiset
- Kohdun kasvaimet
- Patologiset tilat, merkit ja oireet
- Neoplasman metastaasit
- Endometriumin kasvaimet
- Turcot -oireyhtymä
- pembrolitsumabi
Muut tutkimustunnusnumerot
- EIK1005-002
- 2026-525248-13-00 (Ctis)
- KEYNOTE-G56 (Muu tunniste: Merck Sharp & Dohme LLC)
- MK-3475-G56 (Muu tunniste: Merck Sharp & Dohme LLC)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .